Site-directed modification of FVIII

C:\NRPortb\DCCKXC\4427591 - DOC.2(16/21112 This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and ha...

Full description

Saved in:
Bibliographic Details
Main Authors PAN, CLARK Q, MURPHY, JOHN E, STRAUSS, JONATHAN S, TJANDRA, HENDRI, MEI, BAISONG, BARNETT, THOMAS, CHEN, JIANMIN, WANG, DEQIAN, TANG, LIANG
Format Patent
LanguageEnglish
Published 19.07.2012
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
DERIVATIVES THEREOF
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PEPTIDES
SPIRITS
SUGARS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:C:\NRPortb\DCCKXC\4427591 - DOC.2(16/21112 This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
Bibliography:Application Number: AU20120203813